Ashe Andrew D.'s Form 4 filing
Verve Therapeutics, Inc. (VERV) · filed Apr 3, 2025
- Accession no.
- 0000950170-25-050561
- Filed
- Apr 3, 2025
- Trade date
- Apr 1-2, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $11.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ashe Andrew D.CIK 0001573163 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 1, 2025 | Common Stock | MOption exerciseAcquired | +9,000 | –F1 | – | 351,509 | Direct | |
| Apr 2, 2025 | Common Stock | SSaleDisposed | −2,681 | $4.15 | −$11,126.15 | 348,828 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 1, 2025 | Common Stock | MOption exerciseDisposed | −9,000 | $0.00 | $0 | 27,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.
Referenced by the price of 1 transaction in Table I.
Remarks
President, Chief Operating Officer and General Counsel